Price:
Rs. 70,000.00
Sample Type: Tissue
Fasting Not Required
Notes: N8223
Frequently Asked Questions (FAQ's):
What does this test evaluate?
It assesses homologous recombination deficiency (HRD) and related somatic mutations associated with cancer progression and treatment response.
Who should consider this test?
Patients diagnosed with breast, ovarian, prostate, or pancreatic cancers, especially those eligible for targeted therapy.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses high-accuracy next-generation sequencing (NGS) technology and advanced bioinformatics to deliver reliable HRD scoring.
Why is HRD status important in cancer treatment?
HRD status helps determine the effectiveness of PARP inhibitors and other targeted therapies, enabling personalized treatment decisions.
Is a tissue biopsy required for this test?
Yes, tumor tissue is preferred, but liquid biopsy options may be available based on clinical need.
Do I need to fast before giving the sample?
No fasting is needed for this test.
How long does Metropolis Healthcare take to provide the results?
Reports are typically available within 14–18 working days depending on sample type and complexity.
How can Metropolis Healthcare support follow-up testing?
Metropolis Healthcare provides expert oncology panels and repeat monitoring options to track treatment response and genetic evolution